Literature DB >> 22180365

Dual effects of heparin on BMP-2-induced osteogenic activity in MC3T3-E1 cells.

Shin Kanzaki1, Wataru Ariyoshi, Tetsu Takahashi, Toshinori Okinaga, Takeshi Kaneuji, Sho Mitsugi, Keisuke Nakashima, Toshiyuki Tsujisawa, Tatsuji Nishihara.   

Abstract

Heparin displays several types of biological activities by binding to various extracellular molecules, including pivotal roles in bone metabolism. We have previously reported that heparin competitively inhibits the binding activity of bone morphogenic protein-2 (BMP-2) to BMP and the BMP receptor (BMPR) and suppresses BMP-2 osteogenic activity. In the present study, we examined whether heparin affects osteoblast differentiation induced by BMP-2 at various time points in vitro. We found that 72 h of treatment with heparin inhibited alkaline phosphatase (ALP) activity. However, 144 h of treatment enhanced the ALP activity in BMP-2-stimulated MC3T3-E1 cells. Although heparin decreased the phosphorylation of Smad1/5/8 after 0.5 h of culture, prolonged periods of culture with heparin enhanced the Smad phosphorylation. In addition, 72 h of treatment with heparin enhanced the mRNA expression of runx2 and osterix in BMP-2-stimulated MC3T3-E1 cells. Furthermore, the mRNA expression of BMP antagonists and inhibitory Smads induced by BMP-2 was preferentially blocked by heparin at the 24 and 48 h time points. These findings indicate biphasic effects of heparin on BMP-2 activity and suggest that heparin has complex effects on the BMP-2 osteogenic bioactivities. Prolonged culture with heparin stimulated BMP-2-induced osteogenic activity via down-regulation of BMP-2 antagonists and inhibitory Smads.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22180365     DOI: 10.1016/s1734-1140(11)70642-9

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  8 in total

1.  Heparin-dopamine functionalized graphene foam for sustained release of bone morphogenetic protein-2.

Authors:  Qingqing Yao; Yangxi Liu; Hongli Sun
Journal:  J Tissue Eng Regen Med       Date:  2018-05-18       Impact factor: 3.963

2.  Novel mineralized heparin-gelatin nanoparticles for potential application in tissue engineering of bone.

Authors:  Yuan Yang; Haihao Tang; Alexander Köwitsch; Karsten Mäder; Gerd Hause; Joachim Ulrich; Thomas Groth
Journal:  J Mater Sci Mater Med       Date:  2013-12-06       Impact factor: 3.896

3.  The factor VII-activating protease (FSAP) enhances the activity of bone morphogenetic protein-2 (BMP-2).

Authors:  Elfie Kathrin Roedel; Elisabeth Schwarz; Sandip Madhav Kanse
Journal:  J Biol Chem       Date:  2013-01-22       Impact factor: 5.157

4.  Heparin microparticle effects on presentation and bioactivity of bone morphogenetic protein-2.

Authors:  Marian H Hettiaratchi; Tobias Miller; Johnna S Temenoff; Robert E Guldberg; Todd C McDevitt
Journal:  Biomaterials       Date:  2014-05-28       Impact factor: 12.479

Review 5.  Structural perspective of BMP ligands and signaling.

Authors:  Gregory R Gipson; Erich J Goebel; Kaitlin N Hart; Emily C Kappes; Chandramohan Kattamuri; Jason C McCoy; Thomas B Thompson
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

Review 6.  Heparin, Heparan Sulphate and the TGF-β Cytokine Superfamily.

Authors:  Chris C Rider; Barbara Mulloy
Journal:  Molecules       Date:  2017-04-29       Impact factor: 4.411

7.  Polyelectrolyte Complexes between Polycarboxylates and BMP-2 for Enhancing Osteogenic Differentiation: Effect of Chemical Structure of Polycarboxylates.

Authors:  Masahiko Terauchi; Atsushi Tamura; Asato Tonegawa; Satoshi Yamaguchi; Tetsuya Yoda; Nobuhiko Yui
Journal:  Polymers (Basel)       Date:  2019-08-09       Impact factor: 4.329

8.  Single bout short duration fluid shear stress induces osteogenic differentiation of MC3T3-E1 cells via integrin β1 and BMP2 signaling cross-talk.

Authors:  Zhihui Mai; Zhuli Peng; Sihan Wu; Jinglan Zhang; Lin Chen; Huangyou Liang; Ding Bai; Guangmei Yan; Hong Ai
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.